Pascolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL-4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.[2] Development was discontinued as it showed little benefit.[3]
References
[edit]- ^ Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
- ^ Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov
- ^ Bice JB, Leechawengwongs E, Montanaro A (2014). "Biologic targeted therapy in allergic asthma". Annals of Allergy, Asthma & Immunology. 112 (2): 108 - 115. doi:10.1016/j.anai.2013.12.013.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |